0001567619-22-008716.txt : 20220420
0001567619-22-008716.hdr.sgml : 20220420
20220420163223
ACCESSION NUMBER: 0001567619-22-008716
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220131
FILED AS OF DATE: 20220420
DATE AS OF CHANGE: 20220420
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hawryluk Matthew
CENTRAL INDEX KEY: 0001754470
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38663
FILM NUMBER: 22838519
MAIL ADDRESS:
STREET 1: C/O GRITSTONE ONCOLOGY, INC.
STREET 2: 5858 HORTON STREET, SUITE 210
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Gritstone bio, Inc.
CENTRAL INDEX KEY: 0001656634
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5959 HORTON STREET, SUITE 300
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: (510) 871-6100
MAIL ADDRESS:
STREET 1: 5959 HORTON STREET, SUITE 300
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: Gritstone Oncology, Inc.
DATE OF NAME CHANGE: 20151023
4
1
doc1.xml
FORM 4
X0306
4
2022-01-31
0
0001656634
Gritstone bio, Inc.
GRTS
0001754470
Hawryluk Matthew
C/O GRITSTONE BIO, INC.
5959 HORTON STREET, SUITE 300
EMERYVILLE
CA
94608
0
1
0
0
See Remarks
Common Stock
2022-01-31
4
A
0
21612
0
A
53351
D
Stock Option (Right to Buy)
5.46
2022-01-31
4
A
0
129675
0
A
2032-01-30
Common Stock
129675
129675
D
Represents Restricted Stock Units ("RSUs") which vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Includes 12,139 shares of common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c) and 31,412 RSUs which vest over time measured from the grant date.
One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from January 31, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Executive Vice President and Chief Business Officer
/s/ Rahsaan Thompson, Attorney-in-Fact for Matthew Hawryluk
2022-04-20